Enobia Pharma Inc.

Presenter: Robert Heft, President & CEO

Company Profile

Enobia develops therapies to treat serious genetic bone disorders for which there are no approved treatments. Our lead product, ENB-0040 (human recombinant tissue non-specific alkaline phosphatase), is a subcutaneous bone-targeted for hypophosphatasia and is currently in Phase 2 clinical studies.

Investors

CTI Life Sciences Fund L.P., Desjardins Venture Capital, Kirchner Investment Management Corp., Orbimed, T2C2, The Solidarity Fund QFL

Management Team

Robert Heft Ph.D., President & Chief Executive Officer
Luc Cournoyer C.A., Vice-President Finance & Administration
Philippe Crine Ph.D., Vice-President & Chief Scientific Officer
Hal Landy M.D., Vice-President Medical Affairs & Chief Medical Officer
Pierre Léonard Pharm.D., Vice-President Drug Development & Program Management
Julie Anne Smith, Vice-President & Chief Commercial Officer

Presenter Bio

Upon completion of his doctorate at the Massachusetts Institute of Technology in 1986, Dr. Heft joined Continental Pharma Cryosan as its Research Director. Shortly thereafter, he founded IBEX Technologies (Montreal, Quebec) and served as its President until 2001. In 2001, Dr. Heft joined BioMarin Pharmaceutical Inc. (Novato, California) as Vice-President Product Development, after BioMarin acquired the pharmaceutical assets of IBEX. Dr. Heft joined Enobia as President and CEO in 2005. Dr. Heft has served as a Director of the Industrial Biotechnology Association of Canada, the Canadian Genetic Disease Network and of BioCapital a life-sciences venture fund.

Contact

Enobia Pharma Inc.
2901 Rachel Street East, Suite 23
Montreal
Quebec, Canada
H1W 4A4

ph: (514) 596-2901
fx: (514) 596-2749

www.enobia.com
rheft@enobia.com